Botulinum Toxins, Type ATorticollisNeuromuscular AgentsBotulinum ToxinsDystoniaAnti-Dyskinesia AgentsMuscle SpasticityClostridium botulinumDystonic DisordersInjections, IntramuscularBotulismBlepharospasmBotulinum AntitoxinHyperhidrosisSialorrheaParaparesis, SpasticCosmetic TechniquesHemifacial SpasmDystonia Musculorum DeformansSkin AgingMuscle Relaxants, CentralNeck MusclesHypohidrosisSensation DisordersGlobus PallidusInjectionsCerebral PalsySpasmCryoanesthesiaTreatment OutcomeReceptors, Dopamine D5HemiplegiaUpper ExtremityNeurotoxinsMeige SyndromeShiga Toxin 2Cervical VertebraeDeglutition DisordersSweat GlandsTremorPain MeasurementElectromyographyTetanus ToxinBasal GangliaFissure in AnoTherapeutic EquivalencyDeep Brain StimulationClostridium botulinum type AParasympatholyticsClostridium botulinum type EStrokeGaitShiga Toxin 1Facial MusclesSeverity of Illness IndexCholera ToxinRange of Motion, ArticularFollow-Up StudiesDouble-Blind MethodProspective StudiesEsophageal AchalasiaT-2 ToxinQuality-Adjusted Life YearsMuscle CrampShiga ToxinsSweating, GustatoryDose-Response Relationship, DrugSpinal Cord InjuriesLethal Dose 50Synaptosomal-Associated Protein 25EnterotoxinsHandwritingPostureNeuromuscular JunctionPainBacterial ToxinsPatient SatisfactionToxins, BiologicalMovement DisordersAntitoxinsOculomotor MusclesUrinary Bladder, OveractiveCost-Benefit AnalysisEquinus DeformityMagnetic Resonance ImagingVoice DisordersClostridium botulinum type B